Akari Therapeutics (AKTX) Goodwill (2025 - 2026)
Akari Therapeutics (AKTX) posted quarterly Goodwill of $8.4 million for Q1 2026, little changed year-on-year from $8.4 million in Q1 2025, and little changed on a QoQ basis from $8.4 million in Q4 2025.
Akari Therapeutics (AKTX) Goodwill (2025 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has reported Goodwill for 2 consecutive years, with $8.4 million the latest figure, recorded in Q1 2026.
- Quarterly Goodwill changed 0.0% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (changed 0.0% YoY) and the FY2025 annual result came in at $8.4 million, changed N/A from the prior year.
- Goodwill was little changed at $8.4 million in Q1 2026 per AKTX's latest filing, from $8.4 million in the prior quarter.
- Over the last five years, Goodwill for AKTX reached as high as $8.4 million in Q1 2025 and fell as low as $8.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.43 Mn |
| Dec 31, 2025 | 8.43 Mn |
| Jun 30, 2025 | 8.43 Mn |
| Mar 31, 2025 | 8.43 Mn |